Pharmaceuticals

A new Health Canada approval for Regeneron's Libtayo offers a breakthrough for high-risk skin cancer patients and a strategic win for the company.

A startup led by ex-Novo Nordisk execs plans a reverse takeover to fund its made-in-Canada generic Ozempic, aiming to disrupt a C$3.5B market.

vTv Therapeutics is nearing a critical milestone with its oral drug for Type 1 diabetes. Can it solve a deadly problem while navigating the financial tightrope?

Facing Nasdaq pressure, Barinthus Bio advances its Clywedog merger and pivotal celiac disease trial, with key data expected in Q4 2026.

With new patents and a $300M war chest, Beren Therapeutics nears an FDA decision for its NPC drug. But can its public benefit model survive the high-risk biotech gauntlet?

A critical safety milestone for PepGen’s PGN-EDODM1 offers a glimmer of hope for myotonic dystrophy patients and highlights a novel strategy in a competitive field.

With the launch of its TED drug Lumvoa, Viridian Therapeutics steps into the commercial ring. But can early momentum and a deep pipeline justify the cost?

A new partnership between Japan's Ono Pharma and US biotech Mediar aims to disrupt the massive fibro-inflammatory disease market by targeting the root cell of scarring.

With a 32% jump in royalty revenue and a game-changing acquisition, Ligand Pharmaceuticals solidifies its market dominance. But is the growth sustainable?

With nearly $800M in cash, Immunovant is all-in on a single drug, IMVT-1402. Can its ambitious six-front clinical strategy justify the burn and win the race?

With $60M in new funding and veteran pharma execs on board, Vedanta Biosciences is set for the pivotal last leg of its Phase 3 trial for VE303.

Priovant's Phase 3 trial for brepocitinib in cutaneous sarcoidosis isn't just about one disease. It's a key move in Roivant's playbook to build a rare disease powerhouse.

Actimed Therapeutics reclaims S-oxprenolol, a promising ALS drug. This isn't just a pipeline shuffle; it's a calculated move to dominate the future of muscle health.

Fosun International’s recent triple award win isn't just a PR victory. It’s a signal of a meticulously crafted strategy where ESG, AI, and financial resilience converge.

With a pill aimed at both heart disease and blindness, BioAge Labs is betting its future on fighting aging itself. Is this the dawn of a new era in medicine?

As Biofrontera preps its Q2 report, investors weigh record revenue and expanded margins against persistent losses and a critical need for cash flow breakeven.

Facing the biotech cash crunch, Context Therapeutics shelves one drug to double down on two others, a strategic pivot that secures its future into late 2027.

The hormone optimization leader's stock tumbles after Q2 results show a net loss and declining revenue, revealing the prolonged impact of its January recall.

Bristol Myers Squibb's large-scale deployment of Schrödinger's Bunsen AI isn't just a software deal; it's a strategic signal for the future of pharma R&D.

As Ascentage Pharma preps its mid-year report, we look beyond the balance sheet at the strategic plays and clinical trials fueling its global oncology ambitions.